Navigation Links
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules
Date:4/8/2008

CHARLOTTESVILLE, Va., April 8, 2008 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes claims to a family of first-in-class new chemical entities, known as trans biopolar carotenoid (or TBC) molecules. In addition, the Company also announced it has been granted corresponding patents from the South African and the New Zealand Patent Offices.

"The issuance of these patents is a vital step in our intellectual property development strategy, furthering our goal of bringing Diffusion Pharmaceutical's first-in-class therapeutics to market. Our highly unique compounds may one day treat patients with a broad range of disorders involving hypoxia," said David G. Kalergis, Diffusion's CEO.

In addition to these newly issued patents, the Company has also filed other U.S. patent applications and numerous corresponding foreign and national-stage applications in major international markets.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. A Phase 1 study for its lead molecule, trans sodium crocetinate (TSC), in healthy subjects was successfully completed in 2007. The company is now initiating proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit http://www.diffusionpharma.com.


'/>"/>
SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. Microbia Announces Name Change to Ironwood Pharmaceuticals
4. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
5. Memory Pharmaceuticals Receives Nasdaq Notification
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
8. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. VIA Pharmaceuticals Complies With NASDAQ Rule
11. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 24, 2016 , ... Last week, Callan Capital, an integrated wealth management firm ... Future of San Diego Life Science event at the Estancia La Jolla Resort and ... event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem ...
(Date:5/23/2016)... ... 23, 2016 , ... PrecisionAg® Media has released its latest ... The paper outlines the key trends that are creating both opportunities and challenges ... lot of highs and lows as the precision agriculture market has grown and ...
(Date:5/23/2016)... and LONDON , May 23, 2016 /PRNewswire/ ... See Frontage Boost Efficiency by 40% - Frontage Implement ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... labs in the United States and ... to be deployed across its laboratory facilities. In addition to serving ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
Breaking Biology Technology:
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):